Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers

Journal of Clinical Pharmacology

Volumn 46, Issue 7, 2006, Pages 792-801

  Li, Susie Xiujiang ^a   Pequignot, Edward ^b   Panebianco, Deborah ^a   Lupinacci, Paul ^c   Majumdar, Anup ^a   Rosen, Laura ^a   Ahmed, Tuli ^a   Royalty, Jane E ^d   Rushmore, Thomas H ^a   Murphy, M Gail ^a   Petty, Kevin J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c VILLANOVA UNIVERSITY   (United States)

^d West Pharmaceuticals Services   (United States)

Author keywords

Aprepitant; CYP2D6; CYP3A4; Dolasetron; Interaction

Indexed keywords

APREPITANT; CYTOCHROME P450 2D6; DOLASETRON MESILATE; DRUG METABOLITE; HYDRODOLASETRON; SEROTONIN ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME METABOLISM; FATIGUE; FEMALE; GEOMETRY; HEADACHE; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VOLUNTEER; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; INDOLES; MALE; MIDDLE AGED; MORPHOLINES; QUINOLIZINES; REFERENCE VALUES; SEROTONIN ANTAGONISTS;

EID: 33745102330     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006288954     Document Type: Article

References (29)

1. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.
2. Warr D, Hesketh P, Gralla R, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822-2830.
3. EMEND capsules (aprepitant). Whitehouse Station, NJ: Merck; 2003. PDR Electronic Library. Available at: http://pdrel.thomsonhc.com/pdrel/librarian. Accessed January 31, 2005.
4. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin: the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21: 4112-4119.
5. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19:1759-1767.
6. Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003;25:1407-1419.
7. Shah AK, Gallagher SC, Latimer L, Cullen MT, Hunt TL. Lack of effect of aprepitant (APR) on the pharmacokinetics (PK) and safety of palonosetron (PALO) [abstract PII-101]. Clin Pharm Ther. 2004;75:P78.
8. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics, I: disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos. 1992;13:693-701.
9. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics, II: absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos. 1993;14:131-141.
10. Boeijinga PH, Galvan M, Baron BM, Dudley MW, Siegel BW, Slone AL. Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol. 1992;219:9-13.
11. Bigaud M, Elands J, Kastner PR, Bohnke RA, Emmert LW, Galvan M. Pharmacology of the human metabolites of dolasetron, an antiemetic 5-HT3 receptor antagonist. Drug Dev Res. 1995;34:289-296.
12. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron: comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996;24:602-609.
13. Reith MK, Sproles GD, Cheng LK. Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug Metab Dispos. 1995;23:806-812.
14. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther. 2003;74:150-156.
15. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17-24.
16. ANZEMET tablets (dolasetron mesylate). Kansas City, Mo: Aventis Pharmaceuticals; 2003. PDR Electronic Library. Available at: http://pdrel.thomsonhc.com/pdrel/librarian. Accessed January 31, 2005.
17. Keung AC, Landriault H, Lefebvre M, et al. Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. Biopharm Drug Dispos. 1997;18:361-369.
18. Hunt TL, Cramer M, Christy-Bittel J, et al. Multiple-dose, placebo-controlled, phase I study of oral dolasetron. Pharmacotherapy. 1996;16:253-260.
19. Kris MG, Pendergrass KB, Navari RM, et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997;15:2135-2138.
20. Perault MC, Bouquet S, Bertschy G, et al. Debrisoquine and dextromethorphan phenotyping and antidepressant treatment. Therapie. 1991;46:1-3.
21. Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res. 2003;23:31-35.
22. Chida M, Yokoi T, Kosaka Y, et al. Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics. 1999;9:601-605.
23. Constanzer ML, Chavez-Eng CM, Dru J, Kline WF, Matuszewski BK. Determination of a novel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors. J Chromatogr B. 2004;807:243-250.
24. Heim MH, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet. 1990;336:529-532.
25. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S- transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol. 1998;51:294-298.
26. Mulder AB, van Lijf HJ, Bon MAM, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther. 2001;70:546-551.
27. Dimmitt DC, Choo YS, Martin LA, Arumugham T, Hahne WF, Weir SJ. Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers, II. Biopharm Drug Dispos. 1999;20:41-48.
28. Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997;54:273-298.
29. Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996; 28:53-59.